相关实验视频

Updated: Jun 26, 2025

Author Spotlight: Investigating the Potential of Chinese Herbal Medicinal Active Dioscin in Treating IgA Nephropathy

Author Spotlight: Investigating the Potential of Chinese Herbal Medicinal Active Dioscin in Treating IgA Nephropathy

Published on: October 13, 2023

沈阳益口服液通过肠道IL-17 / NF-κB通路改善IgA脏病

Huan Song¹, Guo-Qiang Liang², Man-Shu Yu³

¹Nephropathy Department, Affiliated Hospital of Nanjing University of Chinese Medicine, 155 Hanzhong Road, Nanjing, 210029, China; Nephropathy Department, The Suzhou Affiliated Hospital of Nanjing University of Chinese Medicine, 18 Yangsu Road, Suzhou, 215000, China.

Journal of ethnopharmacology

|May 16, 2024

概括

沈阳益口服液 (SOLI) 通过改善肠道屏障功能和调节IL-17/NF-κB通路,减少蛋白尿和炎症,改善IgA脏病 (IgAN) 鼠的脏损伤.

科学领域:

腎臟病學 (nephrology) 是一種醫學.
免疫学免疫学免疫学
药理学药理学是指药理学的学科.

背景情况:

免疫球蛋白A脏病 (IgAN) 是导致患有复杂病源的病的主要原因.
沈阳海口服液 (SOLI) 显示对Igan的临床疗效,但其机制需要阐明.

研究的目的:

在大鼠模型中研究SOLI对Igan的治疗效果.
确定SOLI对肠粘膜屏障的影响,并确定治疗点.
通过网络药理学,分子对接和实验研究来验证发现.

主要方法:

网络药理学和KEGG通路分析确定了SOLI在IGAN中的基因.
使用Igan鼠标模型来评估Soli对脏和肠道参数的影响.
在体外研究中,研究了用SOLI治疗的IEC-6细胞中的IL-17通路.

主要成果:

在Igan大鼠中,SOLI治疗减少了蛋白尿,损伤和IgA沉积.
SOLI使肠粘膜屏障功能正常化,并调节了肠道免疫反应.
SOLI调节了IL-17 / NF-κB通路,减少了促炎性细胞因子.

结论:

索利通过增强肠道粘膜完整性,在Igan大鼠中显示出脏保护作用.
调节肠道IL-17/NF-κB通路似乎是SOLI有效性的关键机制.
通过向肠-轴,Soli可能为Igan提供一种新的治疗策略.

关键词:

通过IL17/NF-κB信号通路.免疫球蛋白A 脏病发作肠道屏障肠道屏障肠道屏障沈阳宜豪口服溶液是什么意思

更多相关视频

Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease

Author Spotlight: Network Pharmacology and Molecular Docking to Decipher the Action of Jiawei Shengjiang San Against Diabetic Kidney Disease

Published on: May 10, 2024

Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase G6PI-Induced RA Mice

Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase G6PI-Induced RA Mice

Published on: January 31, 2020

相关概念视频

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...

Inflammatory Bowel Disease IV: Pharmacological Management

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...